{
    "clinical_study": {
        "@rank": "102550", 
        "arm_group": [
            {
                "arm_group_label": "BI 1034020 intravenous part", 
                "arm_group_type": "Experimental", 
                "description": "single rising doses"
            }, 
            {
                "arm_group_label": "BI 1034020 subcutaneous part", 
                "arm_group_type": "Experimental", 
                "description": "single rising doses"
            }
        ], 
        "brief_summary": {
            "textblock": "Investigation of safety and tolerability of BI 1034020 in healthy male volunteers following\n      intravenous (IV) infusion of subcutaneous (SC) injection of single doses and exploration of\n      the pharmacokinetics and pharmacodynamics of BI 1034020 after single dosing and\n      determination of the bioavailability of subcutaneous injections of BI 1034020"
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy males based upon a complete medical history, including a physical\n             examination, vital signs (blood pressure, pulse rate), 12-lead electrocardiogram, and\n             clinical laboratory tests\n\n          2. Age within the range of 18 to 40 years\n\n          3. Body mass index within the range of 18.5 and 29.9 kg/m2\n\n          4. Signed and dated written informed consent prior to admission to the study in\n             accordance with GCP and local legislation.\n\n        Exclusion criteria:\n\n          1. Any finding in the medical examination (including blood pressure, pulse rate or\n             electrocardiogram) deviating from normal and judged clinically relevant by the\n             investigator. Pulse rate outside the range of 50-90 bpm or blood pressure outside the\n             ranges of 90-140 for systolic and 50-90 mmHg for diastolic blood pressure if\n             confirmed by repeat measurement\n\n          2. Any evidence of a clinically relevant concomitant disease.\n\n          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders.\n\n          4. Surgery of the gastrointestinal tract (except appendectomy).\n\n          5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or\n             neurological disorders.\n\n          6. History of relevant orthostatic hypotension, fainting spells or blackouts.\n\n          7. Chronic or relevant acute infections."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01958060", 
            "org_study_id": "1312.1", 
            "secondary_id": "2011-004615-23"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 1034020 intravenous part", 
                "description": "intravenous part", 
                "intervention_name": "BI 1034020", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 1034020 subcutaneous part", 
                "description": "subcutaneous part", 
                "intervention_name": "BI 1034020", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 1034020 intravenous part", 
                "description": "intravenous part", 
                "intervention_name": "Placebo to BI 1034020", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 1034020 subcutaneous part", 
                "description": "subcutaneous part", 
                "intervention_name": "Placebo to BI 1034020", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "url": "http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1312/1312.1_statement.pdf"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Biberach", 
                        "country": "Germany"
                    }, 
                    "name": "1312.1.1 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ingelheim", 
                        "country": "Germany"
                    }, 
                    "name": "1312.1.2 Boehringer Ingelheim Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1034020 in Healthy Male Volunteers (Partially Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects (%) with drug related adverse events", 
            "safety_issue": "No", 
            "time_frame": "up to 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01958060"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 6 weeks"
            }, 
            {
                "measure": "AUC0-8 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 6 weeks"
            }, 
            {
                "measure": "AUC0-tz (area under the concentration-time curve of the analyte in the plasma over the time interval from 0 to the last measurable time point of the dose)", 
                "safety_issue": "No", 
                "time_frame": "up to 6 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}